Skip to content

Study · Not a test of the peptide alone · 2023

1 result

Stress induced exacerbation of Alzheimer's disease brain pathology is thwarted by co-administration of nanowired cerebrolysin and monoclonal amyloid beta peptide antibodies with serotonin 5-HT6 receptor antagonist SB-399885.

Sharma HS, Feng L, Muresanu DF, Tian ZR, Lafuente JV, Buzoianu AD, Nozari A, Bryukhovetskiy I, Manzhulo I, Wiklund L, Sharma A

International review of neurobiology16 Sept 2023

PMID37783559 (opens in a new tab)DOI10.1016/bs.irn.2023.05.018 (opens in a new tab)PepBankPUB-37783559
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Cerebrolysin.

  1. 01AnimalNot a test of Cerebrolysin aloneOther designEfficacy outcome

    In a restraint-stress model, nanowired Cerebrolysin with amyloid beta antibodies and SB399885 attenuated stress-exacerbated Alzheimer's disease brain pathology.

    In plain wordsIn an experimental model, Cerebrolysin with antibodies and SB399885 reduced brain pathology worsened by restraint stress.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseStress-exacerbated brain pathology
    Study

    n: not reported in source

    Restraint stress with Alzheimer's disease pathology
    Outcome group
    Neuroprotection · Nervous system and cognition

    Source sentences

    Summary
    nanodelivery of a multimodal drug cerebrolysin together with monoclonal antibodies (mAb) to amyloid beta peptide (AβP) together with a serotonin 5-HT6 receptor antagonist SB399885 significantly thwarted Alzheimer's disease brain pathology exacerbated by restraint stress

    In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.